"Permissive AKI" with treatment of heart failure

Chirag R Parikh; Steven G Coca

doi:10.1016/j.kint.2019.07.003

"Permissive AKI" with treatment of heart failure

Kidney Int. 2019 Nov;96(5):1066-1068. doi: 10.1016/j.kint.2019.07.003.

Authors

Chirag R Parikh¹, Steven G Coca²

Affiliations

¹ Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: chirag.parikh@jhmi.edu.
² Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: Steven.Coca@mssm.edu.

PMID: 31648696
DOI: 10.1016/j.kint.2019.07.003

Abstract

Renin-angiotensin-aldosterone system inhibitors have proven clinical benefit in management of patients with heart failure with reduced ejection fraction. However, there are no guidelines to manage decline in kidney function that occurs with initiation and titration of renin-angiotensin-aldosterone system agents during management of heart failure. We discuss the complex interplay of kidney function and heart failure in the presence of renin-angiotensin-aldosterone system agents and suggest a clinical algorithm for management of acute decline in kidney function.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Acute Kidney Injury*
Enalapril
Glomerular Filtration Rate
Heart Failure*
Humans
Mineralocorticoid Receptor Antagonists
Renin-Angiotensin System
Stroke Volume

Substances

Mineralocorticoid Receptor Antagonists
Enalapril

Abstract

Publication types

MeSH terms

Substances

Grants and funding